Eytan Herzig

Title: Eytan Herzig: Innovator in CAR-T Cell Therapy

Introduction

Eytan Herzig is a notable inventor based in South San Francisco, California. He has made significant contributions to the field of immunotherapy, particularly in the development of modified NKG2D ligands. His work focuses on enhancing the efficacy of Chimeric Antigen Receptor (CAR) T-cell therapies.

Latest Patents

Eytan Herzig holds one patent titled "Modified non-natural NKG2D ligands that selectively deliver attached heterologous molecules to non-natural NKG2D receptors on CAR-cells." This patent relates to the production of modified, non-natural α1-α2 domains of NKG2D ligands. These ligands are designed to attach polypeptides with specific target-binding properties, such as antibodies, which can be selectively delivered to CARs comprised of modified, non-natural NKG2D receptors on engineered mammalian cells. This innovative approach targets surface-expressed molecules on virus-infected cells, allowing engineered immune cells to effectively attack and eliminate these cells.

Career Highlights

Throughout his career, Eytan has worked with several prominent organizations. He has been associated with Xyphos Biosciences Inc. and the J. David Gladstone Institutes. His experience in these institutions has contributed to his expertise in the field of immunotherapy and CAR T-cell technology.

Collaborations

Eytan has collaborated with notable colleagues, including Kaman C Kim and Nigel Killeen. These partnerships have furthered his research and development efforts in the realm of modified NKG2D ligands and CAR T-cell therapies.

Conclusion

Eytan Herzig is a pioneering inventor whose work in modified NKG2D ligands has the potential to revolutionize CAR T-cell therapies. His contributions to immunotherapy highlight the importance of innovation in the fight against cancer and viral infections.